BOSTON, Mass., Jan. 30, 2026 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) (the “Company” or “Standard BioTools”) today announced it has completed the previously announced sale of SomaLogic ...

Illumina Inc. (Nasdaq: ILMN), a genomics and molecular diagnostics company headquartered in San Diego, closed in late January on its acquisition of Boulder-based biotech firm SomaLogic Inc.

We're definitely into long term investing, but some companies are simply bad investments over any time frame. We really hate to see fellow investors lose their hard-earned money. Anyone who held ...

Standard BioTools, which focuses on next-generation technologies for biomedical research, stated that its continuing operations are on track to achieve positive adjusted EBITDA in 2026. The company ...

Received $350 Million in upfront cash at closing; Up to $425 Million in total proceeds inclusive of near-term earnout payments Approximately $550 Million in cash & cash equivalents on balance sheet at ...

(MENAFN- GlobeNewsWire - Nasdaq) Received $350 Million in upfront cash at closing; Up to $425 Million in total proceeds inclusive of near-term earnout payments Approximately $550 Million in cash & ...

Standard BioTools (NASDAQ:LAB) shares jumped as much as 19% premarket on Monday after the company announced the sale of its SomaLogic business to Illumina (NASDAQ:ILMN) for an aggregate cash ...